Forte Biosciences Inc (FBRX NASDAQ) stock market data APIs
$13.6763
0.09(0.7%)
as of July 3, 2025
Try our APIs with
free plan!
Forte Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Prev. Close
13.6763
Open
13.7657
High
14.4313
Low
13.23
52 wk Range
4.11-28.68
Market Cap
169 M
Shares Outstanding
12 214 K
EPS
-1.1191
Beta
2.862
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Forte Biosciences Inc data using free add-ons & libraries
Get Forte Biosciences Inc Fundamental Data
Forte Biosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -44 879 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.95
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Forte Biosciences Inc News
New
Forte Biosciences stock falls after pricing capital raise of $75M via securities offering
Forte Biosciences (NASDAQ:FBRX [https://seekingalpha.com/symbol/FBRX]) has announced the pricing [https://seekingalpha.com/pr/20146901-forte-biosciences-announces-pricing-of-75-million-public-offering...
Forte Biosciences Announces Pricing of $75 Million Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a publ...
Forte's celiac disease drug shows positive results in Phase 1b trial
DALLAS - Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biotech company with a market capitalization of $96.51 million, reported positive data from a Phase 1b trial of its lead drug candidate...
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
-FB-102 Has Demonstrated Potentially Best in Class Activity including Superiority to Standard of Care in GvHD -Proof of Concept Pre-clinical Data in Additional Indications with Large Market Potential...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
